source
- Vedanta Biosciences secures $60 million to complete Phase 3 trial of C. difficile microbiome therapyVedanta Biosciences, a Cambridge, MA biotech focused on microbiome therapeutics, announced it has raised $60 million in new financing. The capital will be used to advance its lead candidate target…
- LifeMine Therapeutics secures $263 million to develop safer transplant immunosuppressantLifeMine Therapeutics announced it has raised a total of $263 million through two venture financing rounds. The capital, which includes a newly disclosed $75 million Series D round, will be used t…